The goal ofthe University of lowa / Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Developmental Research Program is to support innovative, scientifically sound projects that investigate a question pertaining to translational lymphoma research. This program was highly successful with past and current support over the past 4 years going to 13 developmental research projects. Three of these projects have received external, peer-reviewed NCI funding or a fundable priority score, 3 received a second year of funding, and 3 provided data that was instrumental for the major research projects selected for this renewal. The Developmental Research Program will provide up to $50,000 for one year ($25,000 from UI/MC SPORE funds and a matching $25,000 from institutional resources) to each of four projects each year with the possibility of a second year of support based on progress. It is anticipated that support of developmental research projects will continue to result in the generation of new hypotheses that will be tested in full UI/MC SPORE-sponsored projects or through peer reviewed external grant support. The long-term goal of the UI/MC SPORE program is to translate the findings generated by developmental projects into a reduction in the incidence and mortality rates of lymphoma. More specifically, the objectives ef the Developmental Research Program are to: (1) encourage innovative translationally-relevant laboratory, population and clinical studies in lymphoma and chronic lymphocytic leukemia;(2) foster extensive collaboration between basic science, population science and clinical disciplines in translational research in lymphoma;and, (3) generate new hypotheses to be tested in large-scale research projects or clinical trials that may lead to significant reduction of lymphoma incidence and mortality. Brief outlines of four developmental research projects from investigators at the University of lowa and the Mayo Clinic are included to demonstrate the depth and breadth of ongoing research that can be applied to the translational lymphoma research at these institutions and could be eligible for UI/MC SPORE Developmental Program support.
The UI/MC SPORE in Lymphoma Developmental Research Program (DRP) was established to fund early phase research that takes maximum advantage of UI/MC SPORE resources to generate feasibility data for projects that have the highest translational potential. The DRP encourages proposals from investigators in related disciplines se as to rapidly translate new treatment concepts to patients.
|Makkouk, Amani; Weiner, George J (2015) Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 75:10-May|
|Xing, Xiaoming; Flotte, Thomas J; Law, Mark E et al. (2015) Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma. Appl Immunohistochem Mol Morphol 23:580-9|
|Workalemahu, Grefachew; Wang, Hong; Puan, Kia-Joo et al. (2014) Metabolic engineering of Salmonella vaccine bacteria to boost human V?2V?2 T cell immunity. J Immunol 193:708-21|
|Witzig, Thomas E; Maurer, Matthew J; Stenson, Mary J et al. (2014) Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. Am J Hematol 89:417-22|
|Hu, Guangzhen; Lou, Zhenkun; Gupta, Mamta (2014) The long non-coding RNA GAS5 cooperates with the eukaryotic translation initiation factor 4E to regulate c-Myc translation. PLoS One 9:e107016|
|Cerhan, James R; Berndt, Sonja I; Vijai, Joseph et al. (2014) Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet 46:1233-8|
|Skibola, Christine F; Slager, Susan L; Berndt, Sonja I et al. (2014) Medical history, lifestyle, family history, and occupational risk factors for adult acute lymphocytic leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:125-9|
|Aschebrook-Kilfoy, Briseis; Cocco, Pierluigi; La Vecchia, Carlo et al. (2014) Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:98-105|
|Morton, Lindsay M; Slager, Susan L; Cerhan, James R et al. (2014) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:130-44|
|Vajdic, Claire M; Landgren, Ola; McMaster, Mary L et al. (2014) Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:87-97|
Showing the most recent 10 out of 229 publications